Neoantigens and Neoepitope Targeted Preclinical Studies:
A synDNA vaccine delivering neoAg collections controls heterogenous, multifocal murine lung and ovarian tumors via robust T cell generation
Bhojnagarwala PS, Perales-Puchalt A, Cooch N, Sardesai NY and Weiner DB. Mol Ther Oncolytics. 2021
Neoantigen vaccines for cancer: ready for primetime
Perales-Puchalt A, Cooch N, Shende A, Sardesai NY. Immuno-Oncology Insights. 2020
Synthetic DNA multi-neoantigen vaccine drives predominately MHC class I CD8+ T cell mediated effector immunity impacting tumor challenge
Duperret EK, Perales-Puchalt A, Barlow J, Hiranjith GH, Chaudhuri A, Sardesai NY, Weiner DB Cancer Immunol Res. 2018.
A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity
Walters JN, Ferraro B, Sardesai NY, Weiner DB, et al. Mol Ther. 2017.
A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques
Mothe B, Hu X, Sardesai NY, Brander C, et al. J Transl Med. 2015.
Altered Response Hierarchy and Increased T-Cell Breadth upon HIV-1 Conserved Element DNA Vaccination in Macaques
Kulkarni V, Valentin A, Sardesai NY, Gall SL, Mothe B, Felber BK, et al. PLoS One 2014.
Multivalent TB vaccines targeting the esx gene family generate potent and broad cell-mediated immune responses superior to BCG
Villarreal DO, Walters JN, Laddy D, Yan J, Weiner DB. Hum Vaccin Immunother. 2014 Aug.
HIV-1 p24gag Derived Conserved Element DNA Vaccine Increases the Breadth of Immune Response in Mice
Kulkarni V, Rosati M, Valentin A, Sardesai NY, Felber BK, et al. PLoS One. 2013.
Clinical Safety, Immunogenicity, and Efficacy Studies with the Optimized DNA-EP Technology:
Immunotherapy targeting HPV 16/18 generates potent immune responses in HPV-Associated Head and Neck Cancer
Aggarwal, C, Cohen RB, Morrow MP, Weiner DB, Bagarazzi ML, et al. Clin Cancer Res 2018.
Clinical and Immunological Biomarkers for Histologic Regression of High Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy
Morrow MP, Sardesai NY, Weiner DB, Trimble C, Bagarazzi ML, et al. Clin Cancer Res 2017.
Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100
Morrow MP, Kraynyak K, Sardesai NY, Bagarazzi ML, et al. Mol Therapy Oncolytics 2016.
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomized, double-blind, placebo-controlled phase 2b trial
Trimble C, Morrow MP, Kraynyak K, Sardesai NY, Weiner DB, Bagarazzi ML, et al. The Lancet 2015.
Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses
Bagarazzi ML, Weiner DB, Sardesai NY, et al. Sci Transl Med. 2012.
Synthetic Consensus HIV-1 DNA Induces Potent Cellular Immune Responses and Synthesis of Granzyme B, Perforin in HIV Infected Individuals
Morrow MP, Tebas P, Sardesai NY, Weiner DB, Bagarazzi ML, et al. Mol Therapy 2014.
Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery
Kalams SA, Parker SD, Sardesai NY, Weiner DB, et al. J Infect Dis. 2013.
Tolerability of intramuscular and intradermal delivery by CELLECTRA® adaptive constant current electroporation device in healthy volunteers
Diehl MC, Lee JC, Sardesai NY, Bagarazzi ML, et al. Hum Vaccin Immunother. 2013.
Cancer Antigens and Immuno-oncology Combinations Targeted by Optimized DNA-EP Technology:
Synergy of immune checkpoint blockade with a novel synthetic consensus DNA vaccine targeting TERT
Duperret EK, Wise MC, Weiner DB, et al. Molecular Therapy 2017.
Tapping the Potential of DNA Delivery with Electroporation for Cancer Immunotherapy
Kraynyak KA, Bodles-Brakhop A, Bagarazzi M. Curr Top Microbiol Immunol. 2015.
Novel and enhanced anti-melanoma DNA vaccine targeting the tyrosinase protein inhibits myeloid-derived suppressor cells and tumor growth in a syngeneic prophylactic and therapeutic murine model
Yan J, Tingey C, Sardesai NY, Weiner DB, et al. Cancer Gene Ther. 2014.
Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity
Yan J, Pankhong P, Sardesai NY, Weiner DB, et al. Cancer Immunol Res. 2013.
Co-delivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responses
Ferraro B, Cisper NJ, Sardesai NY, Weiner DB, et al. Hum Vaccin. 2011.
Reviews on DNA Vaccines & Immunotherapies:
Human papillomavirus therapeutic vaccines: targeting viral antigens as immunotherapy for precancerous disease and cancer
Morrow MP, Yan J, Sardesai NY. Expert Rev Vaccines 2013.
Electroporation delivery of DNA vaccines: prospects for success
Sardesai NY, Weiner DB. Curr Opin Immunol. 2011.
DNA Drugs Come of Age
Morrow MP, Weiner DB. Scientific American. 2010.
DNA vaccines: ready for prime time?
Kutzler MA, Weiner DB. Nat Rev Genet. 2015.